It was planned to enroll 2 subgroups of HER-2-negative patients into the study: group A, ER+ and/or PR+; group B, ER−/PR− (i.e., triple-negative breast cancer (TNBC)), and the sample size of 20 patients per group was deemed adequate. The gene discussed is ERBB2; the disease is triple-negative breast carcinoma.